Case report demonstrating effectiveness of sorafenib in multiple lung and bone metastases of renal cell carcinoma

Abstract

The current study presents the case of a 59-year-old male with advanced-stage renal cell carcinoma and bone metastases in the proximal femur and ilium (cT3aN3M1; stage IV). Resection of the primary renal cell cancer and palliative surgery with a γ-nail for an impending fracture of the right proximal femur were performed, followed by radiotherapy. Sorafenib, a multi-kinase inhibitor that blocks the raf and tyrosine kinases of the vascular endothelial and platelet-derived growth factor receptors, was administered for 9 months, resulting in a marked improvement in the metastatic ilium and a reduction in the extent of the lung metastases. The patient suffered minor adverse effects, including a skin rash and mild diarrhea, but remained alive at the time of follow-up at 36 months post-surgery. Sorafenib demonstrated efficacy against the bone metastasis of metastatic renal cell carcinoma.